Show simple item record

hal.structure.identifierInstitut Droit et Santé [IDS - U1145]
dc.contributor.authorBocquet, François*
hal.structure.identifierInstitut Droit et Santé [IDS - U1145]
dc.contributor.authorPaubel, Pascal*
hal.structure.identifier
dc.contributor.authorFusier, Isabelle*
hal.structure.identifier
dc.contributor.authorCordonnier, Anne-Laure*
hal.structure.identifierLaboratoire d'Economie de Dauphine [LEDa]
dc.contributor.authorLe Pen, Claude*
hal.structure.identifier
dc.contributor.authorSinègre, Martine*
dc.date.accessioned2014-07-15T10:36:36Z
dc.date.available2014-07-15T10:36:36Z
dc.date.issued2014
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/13717
dc.descriptionISPOR 19th Annual International Meeting Research Abstractsen
dc.language.isoenen
dc.subjectEPO marketsen
dc.subject.ddc334en
dc.subject.classificationjelI.I1.I12en
dc.subject.classificationjelI.I1.I11en
dc.titleA Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Marketsen
dc.typeArticle accepté pour publication ou publié
dc.contributor.editoruniversityotherParis Descartes University;France
dc.description.abstractenObjectives Analyze factors influencing Erythropoietins (EPO) biosimilars (copies of patented EPO) (BIOSIM-EPO) uptakes in key global markets. Identify, if possible, country profiles where BIOSIM-EPO have taken market shares. Methods Countries inclusion criteria: legal definition and regulatory framework for biosimilars close to the EU ones; at least 3 years of experience with BIOSIM-EPO in 2012; national biological market value higher than US$ 2.5 billion. Factors evaluated: national EPO market sizes, EPO retail/hospital distribution mixes, existence of policy incentives that promote BIOSIM-EPO prescriptions or substitution and BIOSIM-EPO prices relative to reference EPO. Data on medicine volumes, values and ex-manufacturer prices for all EPOs (alfa, BIOSIM-EPO (EPO alfa biosimilar), beta and second-generation ones) were provided by IMS Health. Volumes were calculated in DDD (Defined Daily Doses) and prices in euros per DDD. Data were available from 2007 until 2012. Results EU-5 and Japan have been included. Germany: small-sized market, dominant retail market distribution, incentives to prescribe BIOSIM-EPO (quotas) and to substitute patented for ‘bioidenticals’ EPO, high BIOSIM-EPO uptakes (30.4% in 2012). Spain and Italy: medium-sized markets, dominant hospital distribution, no incentives, 11.5% and 8.6% BIOSIM-EPO uptakes respectively. Japan: the largest market, mixed distribution channels, no incentives, 6.8% BIOSIM-EPO uptake. France: large-sized market, dominant retail market distribution, no incentives, 5.8% BIOSIM-EPO uptake. The UK: the smallest market, mixed distribution channels, no incentives, 2.0% BIOSIM-EPO uptake. The price differences between BIOSIM-EPO and their reference play no role at a global level (e.g. -10.8% in Germany and -26.9% in Japan). Conclusions This study proved that EPO markets are highly country specific. There is no single specific profile for countries in which BIOSIM-EPO have significantly penetrated the market. Providing national prescription and substitution incentives is the only determining factor for BIOSIM-EPO uptakes. National EPO market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO prices relative to reference EPO are not significant factors.
dc.relation.isversionofjnlnameValue in Health
dc.relation.isversionofjnlvol17en
dc.relation.isversionofjnlissue3en
dc.relation.isversionofjnldate2014-05
dc.relation.isversionofjnlpagesA11en
dc.relation.isversionofdoi10.1016/j.jval.2014.03.072en
dc.relation.isversionofjnlpublisherElsevieren
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen
dc.description.halcandidateoui
dc.description.readershiprecherche
dc.description.audienceInternational
dc.relation.Isversionofjnlpeerreviewedoui
hal.identifierhal-01507262*
hal.version1*
hal.update.actionupdateMetadata*
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record